Candel Therapeutics Reports 24.5-Month Survival in Lung Cancer Trial
Phase 2a data show aglatimagene plus valacyclovir exceeded standard-of-care survival benchmarks in advanced NSCLC patients who failed immunotherapy.
Candel Therapeutics on Wednesday announced publication of final Phase 2a clinical trial results showing its experimental gene therapy combination produced a median overall survival of 24.5 months in patients with unresectable Stage III or IV non-small cell lung cancer who had not responded adequately to immune checkpoint inhibitor therapy.
The Needham, Massachusetts-based biopharmaceutical company said the figure substantially exceeded historical benchmarks associated with docetaxel, the standard chemotherapy option typically offered to patients in this treatment setting. The trial, registered as NCT04495153, tested aglatimagene besadenovec paired with valacyclovir and was designed to evaluate the combination's ability to reactivate the immune system on a systemic level.
Read more Diversis Capital Acquires Majority Stake in Tideworks Technology →
Candel, which trades on Nasdaq under the ticker CADL, describes itself as a clinical-stage company focused on multimodal immunotherapy approaches for cancer patients. The publication of Phase 2a data marks a significant milestone for the program, as peer-reviewed results provide the scientific foundation typically required before advancing to larger, confirmatory trials.
The results are notable given the limited options available to NSCLC patients who progress after immunotherapy, a population with historically poor prognoses and few effective second-line alternatives. Independent analysts and oncology researchers generally view durable survival improvements over docetaxel as a meaningful clinical bar in this indication.
Continue reading at GlobeNewswire - Industry News on Financial Services.
